Navigation

Published technology appraisals

This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.

More information on the published appraisals list.

For technology appraisal guidance organised by category, use Find guidance in the main header area above.

Searching for specific technology appraisal guidance?

Published appraisals

Results 21-40 of 308

Ref Title Date Issued Review
TA11 Arrhythmias - implantable cardioverter defibrillators (ICDs) (TA11) (replaced by TA95) (withdrawn) Sep 2000 TBC
TA50 Leukaemia (chronic myeloid) - imatinib (TA50) (replaced by TA70) (withdrawn) Oct 2002 TBC
TA14 Hepatitis C - alpha interferon and ribavirin (TA14) (replaced by TA75) (withdrawn) Oct 2000 TBC
TA16 Knee joints (defective) - autologous cartilage transplantation (TA16) (replaced by TA89) (withdrawn) Dec 2000 TBC
TA19 Alzheimer's disease - donepezil, rivastigmine and galantamine (TA19) (replaced by TA111) (withdrawn) Jan 2001 TBC
TA20 Motor neurone disease - riluzole (TA20) Jan 2001 TBC
TA22 Obesity - orlistat (TA22) (replaced by CG43) (withdrawn) Mar 2001 TBC
TA23 Brain cancer - temozolomide (TA23) Apr 2001 TBC
TA24 Wound care - debriding agents (TA24) (replaced by CG74) Apr 2001 TBC
TA25 Pancreatic cancer - gemcitabine (TA25) May 2001 TBC
TA27 Osteoarthritis and rheumatoid arthritis - cox II inhibitors (TA27) (replaced by CG59 and CG79) (withdrawn) Jul 2001 TBC
TA29 Leukaemia (lymphocytic) - fludarabine (TA29) Sep 2001 TBC
TA31 Obesity - sibutramine (TA31) (replaced by CG43) (withdrawn) Oct 2001 TBC
TA71 Ischaemic heart disease - coronary artery stents (TA71) Oct 2003 Nov 2004
TA32 Multiple sclerosis - beta interferon and glatiramer acetate (TA32) Jan 2002 TBC
TA35 Arthritis (juvenile idiopathic) - etanercept (TA35) Mar 2002 TBC
TA37 Lymphoma (follicular non-Hodgkin's) - rituximab (TA37) (replaced by TA137) Mar 2002 TBC
TA41 Pregnancy - routine anti-D prophylaxis for RhD-negative women (TA41) (replaced by TA156) (withdrawn) May 2002 TBC
TA36 Rheumatoid arthritis - etanercept and infliximab (TA36) (replaced by TA130 and TA195) Mar 2002 TBC
TA39 Smoking cessation - bupropion and nicotine replacement therapy (TA39) (replaced by PH10) (withdrawn) Mar 2002 TBC

This page was last updated: 16 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.